BioCentury

7:00 AM GMT, Jun 30, 2016
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)

Infectious disease

INDICATION: Tuberculosis

In vitro, cell culture and mouse studies identified a carboxamide-based MmpL3 inhibitor that could

Read the full 169 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.